Clinical Trial Update: Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) [Phase 2]

View source ↗

Summary

Phase 2 trial update indicates Northera (droxidopa) improved symptoms in Postural Tachycardia Syndrome and Vasovagal Syncope, though the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postural Tachycardia Syndrome
• Vasovagal Syncope

Drugs mentioned

• Northera (droxidopa)

Snippet

Sponsor: New York Medical College | Conditions: Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS) | Phase 2 | Status: TERMINATED